Calidi Biotherapeutics (CLDI) Non-Current Debt (2022 - 2025)

Calidi Biotherapeutics has reported Non-Current Debt for 4 years, with the latest figure at $200000.0 in Q4 2025.

• On a quarterly basis, Non-Current Debt fell 90.0% year-over-year to $200000.0 in Q4 2025; TTM through Dec 2025 was $200000.0, a 90.0% decrease from a year earlier, with the FY2025 full-year figure at $200000.0, down 90.0% from the prior year.
• Non-Current Debt was $200000.0 for Q4 2025 at Calidi Biotherapeutics, down from $400000.0 in the prior quarter.
• The five-year high for Non-Current Debt was $500.0 million in Q2 2025, with the low at $200000.0 in Q4 2025.
• Average Non-Current Debt over 4 years is $47.2 million, with a median of $2.0 million recorded in 2024.
• The largest YoY upside for Non-Current Debt was 15051.52% in 2025 against a maximum downside of 90.0% in 2025.
• Over 4 years, Non-Current Debt stood at $1.5 million in 2022, then jumped by 37.33% to $2.1 million in 2023, then retreated by 2.91% to $2.0 million in 2024, then sank by 90.0% to $200000.0 in 2025.
• The last three Non-Current Debt figures came in at $200000.0 (Q4 2025), $400000.0 (Q3 2025), and $500.0 million (Q2 2025), per Business Quant data.